drugset / Trial / NCT06533280
VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)
RandomizedSequentialDouble-blindTreatment
Summary
This study will assess safety, tolerability and pharmacokinetic (PK) of VH3739937 in healthy participants.
Timeline
- Start
- 2024-08-02
- Primary completion
- 2024-08-14
- Completion
- 2024-08-14
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | — | Oral |
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Rosuvastatin | Small molecule | — | Oral |
| Subject | ZEGRUVIRIMAT | Small molecule | 100 mg | Oral |
| Subject | ZEGRUVIRIMAT | Small molecule | 500 mg | Oral |